Actively Recruiting
T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas
Led by John M. Buatti · Updated on 2026-03-03
15
Participants Needed
1
Research Sites
157 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial studies whether T2 star (T2\*) magnetic resonance imaging (MRI) and biomarker blood testing can help predict how World Health Organization (WHO) grade IV gliomas (malignant gliomas) might change or progress over time.
CONDITIONS
Official Title
T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 21 years
- Newly diagnosed with WHO grade IV malignant glioma confirmed by pathology
- Karnofsky Performance Status (KPS) greater than 60
- Able to give informed consent for chemotherapy, radiation therapy on the MR Linac, and study procedures
You will not qualify if you...
- History of previous malignancy other than non-melanoma skin cancer within the past 5 years
- History of iron metabolic disorders such as hemochromatosis
- Unable to undergo MRI due to size, claustrophobia, or presence of metal implants or devices
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Iowa Health Care
Iowa City, Iowa, United States, 52245
Actively Recruiting
Research Team
J
John Buatti, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here